Butyltolylquinuclidine
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(2R,3S,4S)-2-butyl-3-p-tolylquinuclidine | |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| ATC code | None |
| PubChem | CID 9903250 |
| ChemSpider | 8013735 |
| Chemical data | |
| Formula | C18H27N |
| Molar mass | 257.414 g/mol |
| |
| |
| (verify) | |
2-Butyl-3-(p-tolyl)quinuclidine (BTQ) is a stimulant DRI.[1] It is one of a number of substituted quinuclidine derivatives developed as potential medications for the treatment of cocaine abuse,[2] and produces similar effects to cocaine in animal studies, although milder and longer lasting.
References
- ↑ Sakamuri, S.; Enyedy, I. J.; Zaman, W. A.; Tella, S. R.; Kozikowski, A. P.; Flippen-Anderson, J. L.; Farkas, T.; Johnson, K. M.; Wang, S. (2003). "2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors". Bioorganic & Medicinal Chemistry 11 (6): 1123–1136. doi:10.1016/S0968-0896(02)00450-9. PMID 12614900.
- ↑ Enyedy, I. J.; Sakamuri, S.; Zaman, W. A.; Johnson, K. M.; Wang, S. (2003). "Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors". Bioorganic & Medicinal Chemistry Letters 13 (3): 513–517. doi:10.1016/S0960-894X(02)00943-5. PMID 12565962.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Friday, August 28, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.